Biotech company Cyxone develops new therapies for the treatment of autoimmune diseases, such as rheumatoid arthritis with the phase IIb candidate Rabeximod. The company reached a milestone in receiving a Notice of Allowance for the US patent of Rabeximod compounds. BioStock contacted CEO Carl-Magnus Högerkorp for a comment on the prospects of the patent.
Read the interview with Cyxone's CEO Carl-Magnus Högerkorp at biostock.se:
https://www.biostock.se/en/2023/04/cyxones-ceo-comments-on-the-us-patent-notice/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/